Antares Pharma, Inc. (ATRS)

R&D to Revenue

12.05%

Quarterly · Period ending:

ATRS logo

ATRS R&D to Revenue

Latest reported12.05%
ATRS Quarterly R&D/Revenue (0.00% → 12.05%)
High-resolution chart · PNG

ATRS r&d to revenue history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Antares Pharma, Inc. R&D to Revenue — Quarterly
Period endingR&D to Revenue
60%
60.7527%
66.6667%
75%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.